#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh

• https://x.com/DrMiniDey/status/2062859225999495638/photo/1

#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At

• https://x.com/Yuz6Yusof/status/2062828345583186416/photo/1

#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

• https://x.com/Yuz6Yusof/status/2062442028848296425/photo/1

From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF

Progress of biologics/targeted therapy in SLE We are in a transformative era for SLE, for clinicians and patients. Four targeted therapies are now licensed: belimumab (nephritis and non‑renal), voclosporin and obinutuzumab (nephritis), and anifrolumab (non‑renal). Many agents https://t.co/BuFCmj1hQd

DR JOHN STONE gives Overview Of #IgG4 New non B cell depleter #obexelimab N=194 in RCT To add to B cell depletion w #Inebilizumab Off label but used also #Rituximab #steroids #Immunesuppressives Other investigational drugs Ex #JAKi #EULAR2026 @RheumNow #OP018 #RULARbest https://t.co/Y4saGYcdww

• https://x.com/Janetbirdope/status/2062551135592804656/photo/1
• https://x.com/Janetbirdope/status/2062551135592804656/photo/1
• https://x.com/Janetbirdope/status/2062551135592804656/photo/1

Good news! #Survival in #SLE is improving #SLR of #lupus publications over time in 233 publications Bad news - still a mortality gap! #EULAR2026 @RheumNow @eular_org ABST#POS0684 https://t.co/PVmQI2duYS

• https://x.com/Janetbirdope/status/2062546737198182618/photo/1

Sustained remission in #SLE at 5 yrs w CAR-T 8 severe SLE patients treated with autologous CD19-CAR T cells (Zorpocel; Miltenyi Biomedicine) #antiDNA and #SLEDAI #antiSm ➡️prolonged suppression Big ? - how long will it work for Impressive! @RheumNow #EULAR2026 #EULARbest #729 https://t.co/8iOSImX3w6

• https://x.com/Janetbirdope/status/2062543128117059926/photo/1

Defining the TRM- SLE patient response. Patient eligibility would be the key #EULAR2026 @RheumNow https://t.co/5CzQYgc12K

• https://x.com/bella_mehta/status/2062541630352105599/photo/1
• https://x.com/bella_mehta/status/2062541630352105599/photo/1
• https://x.com/bella_mehta/status/2062541630352105599/photo/1

Treatment for #lupus #brain #fog?! #small #RCT of Memantine a N-methyl-D-aspartate receptor (NDAR) antagonist used in #Alzheimers SLE-more permeability in #brain #SLE -antiDNA cross reacting w NDAR #memantine N=19 v #PBO N=25 showed more improvemt #EULAR2026 @RheumNow POS701 https://t.co/qvHOy9oDS7

• https://x.com/Janetbirdope/status/2062540663443362243/photo/1

#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T

• https://x.com/Yuz6Yusof/status/2062529425246240921/photo/1

ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score Potential adjunct tx for NPSLE? AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s

• https://x.com/RHEUMarampa/status/2062506356192538724/photo/1

@RheumNow WIN Nutrition session at #EULAR2026 (3) 6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal 7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001). @RheumNow

WIN Nutrition session at #EULAR2026 (2) 🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals. 🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies. @RheumNow